HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NPA Internal Review Sparked Suit Against Board Members, Ongoing Changes

This article was originally published in The Rose Sheet

Executive Summary

A review launched after NPA's former CFO filed a wrongful termination complaint in November has invalidated the allegations, but has "also shown that there was some governance that needed to change," says Executive Director and CEO Daniel Fabricant.

You may also be interested in...

NPA, Ex-CFO Weickert Exchange Unsavory Allegations In Legal Crossfire

In lawsuits pending in DC District Court, former NPA CFO Brent Weickert claims he was wrongfully terminated after raising concerns with the trade group's board about CEO Daniel Fabricant's conduct, while NPA is suing to remove board members who allegedly conspired with Weickert to oust Fabricant and serve their own personal interests.

NPA Maintains Limits On Retailer Membership

A proposed change would have removed the requirement that retail members have stores and that 75% of their sales come from natural foods, supplements and related items. But NPA members approved five bylaw amendments to simplify the process of voting for board members.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts